Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

The Centers for Disease Control and Prevention recommend adjunctive antitoxins when systemic anthrax is suspected. Obiltoxaximab, a monoclonal antibody against protective antigen (PA), is approved for treatment of inhalational anthrax in combination with antibiotics and for prophylaxis when alternat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Brent J., Shadiack, Annette M., Carpenter, Sarah, Sanford, Daniel, Henning, Lisa N., Gonzales, Nestor, O'Connor, Edward, Casey, Leslie S., Serbina, Natalya V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038297/
https://www.ncbi.nlm.nih.gov/pubmed/27431219
http://dx.doi.org/10.1128/AAC.01102-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038297/
https://www.ncbi.nlm.nih.gov/pubmed/27431219
http://dx.doi.org/10.1128/AAC.01102-16

Ejemplares similares